Tafenoquine and primaquine do not exhibit clinical neurologic signs associated with central nervous system lesions in the same manner as earlier 8-aminoquinolines

BACKGROUND: Tafenoquine was recently approved for Plasmodium vivax radical cure (KRINTAFEL™) and malaria prevention (ARAKODA™). METHODS: A review of the non-clinical and clinical literature was conducted to assess whether tafenoquine (and primaquine) exhibit the same neurologic lesions and associate...

Descripción completa

Detalles Bibliográficos
Autores principales: Berman, Jonathan, Brown, Tracey, Dow, Geoffrey, Toovey, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219089/
https://www.ncbi.nlm.nih.gov/pubmed/30400893
http://dx.doi.org/10.1186/s12936-018-2555-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6219089/
https://www.ncbi.nlm.nih.gov/pubmed/30400893
http://dx.doi.org/10.1186/s12936-018-2555-3

Ejemplares similares